Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models.

Schreiber AR, Nguyen A, Bagby SM, Arcaroli JJ, Yacob BW, Quackenbush K, Guy JL, Crowell T, Stringer B, Danaee H, Kalebic T, Messersmith WA, Pitts TM.

Clin Cancer Drugs. 2018;5(1):42-49. doi: 10.2174/2212697X05666180516120907.

2.

Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers.

Danaee H, Kalebic T, Wyant T, Fassan M, Mescoli C, Gao F, Trepicchio WL, Rugge M.

PLoS One. 2017 Dec 19;12(12):e0189953. doi: 10.1371/journal.pone.0189953. eCollection 2017.

3.

A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.

Almhanna K, Wright D, Mercade TM, Van Laethem JL, Gracian AC, Guillen-Ponce C, Faris J, Lopez CM, Hubner RA, Bendell J, Bols A, Feliu J, Starling N, Enzinger P, Mahalingham D, Messersmith W, Yang H, Fasanmade A, Danaee H, Kalebic T.

Invest New Drugs. 2017 Oct;35(5):634-641. doi: 10.1007/s10637-017-0473-9. Epub 2017 May 19.

PMID:
28527133
4.

TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study.

Bang YJ, Takano T, Lin CC, Fasanmade A, Yang H, Danaee H, Asato T, Kalebic T, Wang H, Doi T.

Cancer Res Treat. 2018 Apr;50(2):398-404. doi: 10.4143/crt.2017.074. Epub 2017 May 10.

5.

Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C.

Almhanna K, Miron ML, Wright D, Gracian AC, Hubner RA, Van Laethem JL, López CM, Alsina M, Muñoz FL, Bendell J, Firdaus I, Messersmith W, Ye Z, Fasanmade AA, Danaee H, Kalebic T.

Invest New Drugs. 2017 Apr;35(2):235-241. doi: 10.1007/s10637-017-0439-y. Epub 2017 Feb 11.

PMID:
28188407
6.

Antibody-drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies.

Almhanna K, Prithviraj GK, Veiby P, Kalebic T.

Pharmacol Ther. 2017 Feb;170:8-13. doi: 10.1016/j.pharmthera.2016.10.007. Epub 2016 Oct 18. Review.

PMID:
27765652
7.

Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies.

Almhanna K, Kalebic T, Cruz C, Faris JE, Ryan DP, Jung J, Wyant T, Fasanmade AA, Messersmith W, Rodon J.

Clin Cancer Res. 2016 Oct 15;22(20):5049-5057. Epub 2016 May 13.

8.

Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.

Smith DC, Kalebic T, Infante JR, Siu LL, Sullivan D, Vlahovic G, Kauh JS, Gao F, Berger AJ, Tirrell S, Gupta N, Di Bacco A, Berg D, Liu G, Lin J, Hui AM, Thompson JA.

Invest New Drugs. 2015 Jun;33(3):652-63. doi: 10.1007/s10637-015-0230-x. Epub 2015 Mar 18.

9.

SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia.

Esposito N, Colavita I, Quintarelli C, Sica AR, Peluso AL, Luciano L, Picardi M, Del Vecchio L, Buonomo T, Hughes TP, White D, Radich JP, Russo D, Branford S, Saglio G, Melo JV, Martinelli R, Ruoppolo M, Kalebic T, Martinelli G, Pane F.

Blood. 2011 Sep 29;118(13):3634-44. doi: 10.1182/blood-2011-03-341073. Epub 2011 Aug 5.

PMID:
21821701
10.

c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myelogenous leukemia CD34+ hematopoietic progenitor cells.

Porro A, Iraci N, Soverini S, Diolaiti D, Gherardi S, Terragna C, Durante S, Valli E, Kalebic T, Bernardoni R, Perrod C, Haber M, Norris MD, Baccarani M, Martinelli G, Perini G.

Mol Cancer Res. 2011 Aug;9(8):1054-66. doi: 10.1158/1541-7786.MCR-10-0510. Epub 2011 Jun 21.

11.

Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.

Razis E, Selviaridis P, Labropoulos S, Norris JL, Zhu MJ, Song DD, Kalebic T, Torrens M, Kalogera-Fountzila A, Karkavelas G, Karanastasi S, Fletcher JA, Fountzilas G.

Clin Cancer Res. 2009 Oct 1;15(19):6258-66. doi: 10.1158/1078-0432.CCR-08-1867. Epub 2009 Sep 29.

12.

Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study.

Papotti M, Kalebic T, Volante M, Chiusa L, Bacillo E, Cappia S, Lausi P, Novello S, Borasio P, Scagliotti GV.

J Clin Oncol. 2006 Oct 20;24(30):4818-24.

PMID:
17050866
13.

Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation.

Voorzanger-Rousselot N, Juillet F, Mareau E, Zimmermann J, Kalebic T, Garnero P.

Br J Cancer. 2006 Aug 21;95(4):506-14. Epub 2006 Aug 1.

14.

Epigenetic transitions: towards therapeutic targets.

Kalebic T.

Expert Opin Ther Targets. 2003 Dec;7(6):693-9.

PMID:
14640906
15.

Chemoprevention of lung cancer: new directions.

Szabo E, Kalebic T.

Recent Results Cancer Res. 2003;163:172-81; discussion 264-6. Review.

PMID:
12903853
16.

Epigenetic changes: potential therapeutic targets.

Kalebic T.

Ann N Y Acad Sci. 2003 Mar;983:278-85. Review.

PMID:
12724232
17.

Novel anticancer function of inositol hexaphosphate: inhibition of human rhabdomyosarcoma in vitro and in vivo.

Vucenik I, Kalebic T, Tantivejkul K, Shamsuddin AM.

Anticancer Res. 1998 May-Jun;18(3A):1377-84.

PMID:
9673344
18.

Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R.

Kalebic T, Blakesley V, Slade C, Plasschaert S, Leroith D, Helman LJ.

Int J Cancer. 1998 Apr 13;76(2):223-7.

19.

HIV vaccine trials.

Kalebic T.

Science. 1998 Mar 6;279(5356):1434-6. No abstract available.

PMID:
9508712
20.

The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts.

Toretsky JA, Kalebic T, Blakesley V, LeRoith D, Helman LJ.

J Biol Chem. 1997 Dec 5;272(49):30822-7.

21.

Role of the IGF-I receptor in mutagenesis and tumor promotion.

Blakesley VA, Stannard BS, Kalebic T, Helman LJ, LeRoith D.

J Endocrinol. 1997 Mar;152(3):339-44. Review. No abstract available.

PMID:
9071953
22.

Disruption of the MyoD/p21 Pathway in Rhabdomyosarcoma.

Weintraub M, Kalebic T, Helman LJ, Bhatia KG.

Sarcoma. 1997;1(3-4):135-41.

23.

Suppression of rhabdomyosarcoma growth by fumagillin analog TNP-470.

Kalebic T, Tsokos M, Helman LJ.

Int J Cancer. 1996 Nov 27;68(5):596-9.

24.

Human fetal glial cells constitutively produce HIV-inducing cytokines.

Kalebic T.

Exp Cell Res. 1996 Mar 15;223(2):452-8.

PMID:
8601423
26.

Metastatic human rhabdomyosarcoma: molecular, cellular and cytogenetic analysis of a novel cellular model.

Kalebic T, Judde JG, Velez-Yanguas M, Knutsen T, Helman LJ.

Invasion Metastasis. 1996;16(2):83-96.

PMID:
9030243
27.
28.

The role of the tyrosine kinase domain of the insulin-like growth factor-I receptor in intracellular signaling, cellular proliferation, and tumorigenesis.

Hernández-Sánchez C, Blakesley V, Kalebic T, Helman L, LeRoith D.

J Biol Chem. 1995 Dec 8;270(49):29176-81.

29.

The role of the insulin-like growth factor-I receptor in cancer.

LeRoith D, Werner H, Neuenschwander S, Kalebic T, Helman LJ.

Ann N Y Acad Sci. 1995 Sep 7;766:402-8. Review. No abstract available.

PMID:
7486685
30.

HIV-1 modulates the expression of gelatinase A and B in monocytic cells.

Kalebic T, Masiero L, Onisto M, Garbisa S.

Biochem Biophys Res Commun. 1994 Dec 15;205(2):1243-9.

PMID:
7802656
31.
32.

Organic thiophosphate WR-151327 suppresses expression of HIV in chronically infected cells.

Kalebic T, Schein PS.

AIDS Res Hum Retroviruses. 1994 Jun;10(6):727-33.

PMID:
7521193
33.

Ara-C treatment leads to differentiation and reverses the transformed phenotype in a human rhabdomyosarcoma cell line.

Crouch GD, Kalebic T, Tsokos M, Helman LJ.

Exp Cell Res. 1993 Feb;204(2):210-6.

PMID:
8440318
34.

Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and N-acetylcysteine.

Kalebic T, Kinter A, Poli G, Anderson ME, Meister A, Fauci AS.

Proc Natl Acad Sci U S A. 1991 Feb 1;88(3):986-90.

35.

Astrocyte-conditioned medium stimulates HIV-1 expression in a chronically infected promonocyte clone.

Vitković L, Kalebic T, de Cunha A, Fauci AS.

J Neuroimmunol. 1990 Dec;30(2-3):153-60.

PMID:
2229407
36.

High frequency of double drug resistance in the B16 melanoma cell line.

McMillan TJ, Kalebic T, Stark GR, Hart IR.

Eur J Cancer. 1990;26(5):565-7.

PMID:
2144741
37.

A novel method for selection of invasive tumor cells: derivation and characterization of highly metastatic K1735 melanoma cell lines based on in vitro and in vivo invasive capacity.

Kalebic T, Williams JE, Talmadge JE, Kao-Shan CS, Kravitz B, Locklear K, Siegal GP, Liotta LA, Sobel ME, Steeg PS.

Clin Exp Metastasis. 1988 Jul-Aug;6(4):301-18.

PMID:
3359713
38.

Type IV collagenolytic activity linkage with the metastatic phenotype induced by ras transfection.

Garbisa S, Negro A, Kalebic T, Pozzatti R, Muschel R, Saffiotti U, Liotta LA.

Adv Exp Med Biol. 1988;233:179-86. No abstract available.

PMID:
2851926
39.

Type V collagen in human amnion is a 12 nm fibrillar component of the pericellular interstitium.

Modesti A, Kalebic T, Scarpa S, Togo S, Grotendorst G, Liotta LA, Triche TJ.

Eur J Cell Biol. 1984 Nov;35(2):246-55.

PMID:
6394329
40.

Basement membrane collagen: degradation by migrating endothelial cells.

Kalebic T, Garbisa S, Glaser B, Liotta LA.

Science. 1983 Jul 15;221(4607):281-3.

PMID:
6190230
41.

Laminin receptor on human breast carcinoma cells.

Terranova VP, Rao CN, Kalebic T, Margulies IM, Liotta LA.

Proc Natl Acad Sci U S A. 1983 Jan;80(2):444-8.

42.

Degradation of basement membrane components by vascular endothelial cells: role in neovascularization.

Glaser BM, Kalebic T, Garbisa S, Connor TB Jr, Liotta LA.

Ciba Found Symp. 1983;100:150-62.

PMID:
6197258
43.

Effect of natural protease inhibitors and a chemoattractant on tumor cell invasion in vitro.

Thorgeirsson UP, Liotta LA, Kalebic T, Margulies IM, Thomas K, Rios-Candelore M, Russo RG.

J Natl Cancer Inst. 1982 Nov;69(5):1049-54.

PMID:
6752521
44.

Protease susceptibilities of HMW, 1 alpha, 2 alpha, but not 3 alpha cartilage collagens are similar to type V collagen.

Liotta LA, Kalebic T, Reese CA, Mayne R.

Biochem Biophys Res Commun. 1982 Jan 29;104(2):500-6. No abstract available.

PMID:
7041901

Supplemental Content

Loading ...
Support Center